(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual revenue growth rate of 478.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 47.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.43%.
Collplant Biotechnologies's revenue in 2026 is $389,000.On average, 4 Wall Street analysts forecast CLGN's revenue for 2026 to be $116,424,498, with the lowest CLGN revenue forecast at $28,269,576, and the highest CLGN revenue forecast at $209,396,787. On average, 4 Wall Street analysts forecast CLGN's revenue for 2027 to be $160,703,885, with the lowest CLGN revenue forecast at $35,336,970, and the highest CLGN revenue forecast at $292,993,961.
In 2028, CLGN is forecast to generate $286,849,656 in revenue, with the lowest revenue forecast at $275,599,518 and the highest revenue forecast at $295,287,259.